. 2018 Dec 18;2018:8923520. doi: 10.1155/2018/8923520

Table 2.

Comparison of assessment outcomes among the 3 groups.

Variable	Case number	Group	Week 0	Week 1	Week 2	Week 3	Change after 1 week	Change after 2 weeks	Change after 3 weeks
PASS	18	Four-channel	11 ± 5	23 ± 6^a	29 ± 3^a	31 ± 3^a	12 ± 5	18 ± 4	20 ± 5
	15	Dual-channel	12 ± 8	20 ± 9^a	24 ± 8^ab	28 ± 8^a	8 ± 5^b	12 ± 5^b	16 ± 4^b
	15	Placebo	12 ± 8	20 ± 10^a	21 ± 7^ab	25 ± 8^ab	8 ± 4^b	8 ± 5^bc	13 ± 5^b
BBA	18	Four-channel	3.1 ± 1.3	5.0 ± 1.9^a	8.3 ± 2.4^a	9.2 ± 2.3^a	2.0 ± 1.5	5.2 ± 2.6	6.1 ± 2.5
	15	Dual-channel	3.5 ± 1.6	4.8 ± 2.6^a	6.9 ± 3.0^a	8.7 ± 3.0^a	1.3 ± 1.5	3.4 ± 1.8^b	4.7 ± 1.7^b
	15	Placebo	3.1 ± 2.2	5.1 ± 3.3^a	6.2 ± 3.1^ab	8.0 ± 3.5^a	1.9 ± 1.6	3.1 ± 1.2^b	4.9 ± 1.8
BBS	18	Four-channel	6 ± 5	20 ± 11^a	37 ± 7^a	43 ± 8^a	14 ± 9	31 ± 7	37 ± 8
	15	Dual-channel	6 ± 5	18 ± 15^a	29 ± 16^a	37 ± 13^a	12 ± 12	23 ± 12^b	31 ± 10^b
	15	Placebo	9 ± 10	18 ± 15^a	24 ± 16^ab	29 ± 17^ab	10 ± 8	16 ± 9^bc	21 ± 11^bc
FMA	18	Four-channel	9 ± 6	15 ± 4^a	22 ± 5^a	25 ± 5^a	6 ± 5	13 ± 7	16 ± 8
	15	Dual-channel	8 ± 4	13 ± 7^a	18 ± 9^a	20 ± 7^a	5 ± 4	9 ± 5	12 ± 5
	15	Placebo	8 ± 6	13 ± 8^a	15 ± 8^ab	17 ± 9^ab	5 ± 5	7 ± 7^b	9 ± 6^b
MBI	18	Four-channel	22 ± 9	52 ± 12^a	73 ± 13^a	81 ± 13^a	30 ± 9	51 ± 11	59 ± 11
	15	Dual-channel	23 ± 13	44 ± 20^a	60 ± 17^ab	71 ± 15^a	21 ± 10^b	37 ± 12^b	48 ± 7^b
	15	Placebo	24 ± 13	38 ± 18^abc	47 ± 20^ab	54 ± 25^abc	15 ± 9^b	23 ± 10^bc	31 ± 15^bc

Values are mean ± SD. Change is the value before treatment minus the one at the time indicated. ^aSignificant difference at the p ≤ 0.001 level of confidence compared with the baseline value. ^bSignificant difference at the p ≤ 0.05 level of confidence compared with the four-channel group. ^cSignificant difference at the p ≤ 0.05 level of confidence compared with the dual-channel group.